Record Gathering of South Carolina Life Sciences Industry Honors USC’s Dr. Harris Pastides, AVX Corporation, Prisma’s Youkey for ContributionsIndustry leaders in Greenville salute AVX, Pastides, Youkey for advancing SC life sciences see more
450 industry leaders in Greenville salute honorees for advancing South Carolina’s life sciences, discuss avenues to “Ignite the Future” of fast-growing industry
NOVEMBER 4, 2019 – To resounding applause from a record gathering from 11 countries, 32 states and virtually every county in South Carolina, life sciences leaders at SCBIO 2019 in Greenville saluted three leaders – two individuals and one organization – for profound positive impact and exceptional contributions to the advancement of South Carolina’s $11.4 billion life sciences industry.
Retired University of South Carolina President Dr. Harris Pastides was presented with the South Carolina Life Sciences Hall of Fame Award for his personal championing of the life sciences industry, which today has an $11.4 billion annual economic impact in the Palmetto State, with more than 670 firms directly involved and over 43,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products. The University of South Carolina is a Mission Partner of SCBIO and has been highly instrumental in helping the rapid growth of life sciences in the Palmetto State.
Recently retired as USC’s 28th president, Dr. Pastides has led the school’s eight institutions in 19 locations to high achievement and growth. He took USC’s helm in 2008, launching an unprecedented construction expansion of more than $1 billion in projects, and growing student enrollment by 25 percent to more than 51,000 students. Under his tenure, the USC Honors College has risen to the No. 1 public honors college in the nation and celebrated increased research funding and top rankings in undergraduate and graduate international business, public health, engineering and nursing. In 2016, Dr. Pastides became one of seven Fulbright alumni to receive the inaugural Global Changemaker Award in recognition of his ongoing commitment to transform society and humanity through his work. Before joining USC as dean of the Arnold School of Public Health, Dr. Pastides was chairman of the Department of Biostatistics and Epidemiology at the University of Massachusetts Amherst. He received two masters’ degrees and a Ph.D. in Epidemiology from Yale University. The award was presented by Hank Jibaja, CIO of sponsoring organization Nephron Pharmaceuticals.
Presented with the South Carolina Life Sciences Pinnacle Award for Organizational Contribution to the industry was AVX Corporation of Fountain Inn, represented by Robert J. Fairey, Vice President of the Medical Division of AVX Corporation. A Mission Partner of SCBIO, AVX components are used in most implantable life support devices globally, and the company is expanding its passive component and interconnect product portfolio to serve other segments of the medical electronics industry. With over 20 years’ experience supplying electronic components to the medical device industry, AVX offers leading technology, reliability and a deep understanding of the requirements set forth from the medical industry. AVX’s quality systems lead the industry and support customer-specific change control, documentation, specifications and testing procedures.
A South Carolina native and Clemson University graduate with B.S. and M.S. degrees in Management, Mr. Fairey serves as Vice President, Medical Division for AVX Corporation in Fountain Inn, South Carolina. For over 25 years, he has been involved in developing, manufacturing and marketing capacitors and other AVX components for pacemakers, implantable defibrillators and other lifesaving and life-enhancing products.
Presented with the South Carolina Life Sciences Pinnacle Award for Individual Contribution to the industry was Dr. Jerry Youkey, recently retired EVP and Chief Academic Officer of Prisma Health and Founding Dean of the USC School of Medicine – Greenville. Dr. Youkey joined Greenville Health System (now Prisma) in 1998 and was responsible for expansion of the health system’s research and education activities, creation of its 1200 physician group practice, progressive integration of hospital-physician patient care, and for the growing USC health sciences presence in the Upstate. Dr. Youkey previously served as chief of the department of surgery at Geisinger Medical Center in Danville, Pennsylvania and in the United States Army Medical Corps where he attained the rank of lieutenant colonel. Certified by the American Board of Surgery in general vascular surgery, he is a member of numerous professional societies and widely published. On September 30, 2019 he was designated Founding Dean Emeritus by the University of South Carolina. In recognition of his transformative health care leadership, Governor Henry McMaster conferred upon Dr. Youkey the Order of the Palmetto for his contributions to the state of South Carolina.
The three honorees joined such noted speakers as Johnson & Johnson Innovation leader Michal Preminger, Medtronic VP of Value-Based Partnerships Christian Howell, South Carolina Lt. Governor Pamela Evette, President Jim Clements of Clemson University and more than 50 additional national speakers at SCBIO 2019 – the annual conference which gathers thought leaders and executives from life sciences organizations across the nation annually.
The record 450 attendees who filled Hyatt Regency Greenville included scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America including IQVIA Institute of Human Data Science’s Murray Aitken, EY’s NextWave Wellness and life sciences experts Kim Ramko and Kenny O’Neill, Thomas Hardaway of PhRMA, Prisma Health’s President & CEO Mark O’Halla, and numerous others.
SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.
“The life sciences industry is a significant driver of South Carolina’s growing knowledge economy, and these honorees and this conference are testament to the industry’s growing impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “We’re pleased to honor them for their many contributions and salute them for the advances they have facilitated for this industry.”
As the official state affiliate of BIO, PhRMA and AdvaMed, SCBIO members include hundreds of academic institutions, biotech companies, medtech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental products that transform how we heal, fuel and feed the world.
For additional information on SCBIO, visit www.SCBIO.org.
AVX Corporation is a leading international manufacturer and supplier of advanced electronic components, interconnect, sensing, control, and antenna solutions with 29 manufacturing facilities in 16 countries around the world. AVX offers a broad range of devices including capacitors, resistors, filters, couplers, sensors, controls, circuit protection devices, connectors, and antennas. The company is publicly traded on the New York Stock Exchange (NYSE:AVX).
Greenwood Genetic Center, MUSC affiliate to improve patient access to innovations in genetic servicesMUSC partners with Greenwood Genetic Center see more
The Greenwood Genetic Center (GGC) and the Medical University of South Carolina (MUSC) have signed an affiliation agreement with the goal of providing patients across South Carolina with accessible, high-quality, coordinated and cost-effective genetic services through a collaborative approach to providing medical care. The two entities have worked together informally on clinical consultations, provider education and research for more than a decade. This affiliation seeks to formalize and expand the depth and breadth of the relationship. According to MUSC, a partnership with the state’s most advanced and innovative genetic center was an easy choice.
“I live in Greenwood, and I’ve said for years that a lot people don’t understand what an absolute gem this center is,” said Charles Schulze, chairman of the MUSC Board of Trustees. “They’ve helped almost 100,000 families across the state make incredibly important decisions, unmasked difficult-to-diagnose conditions, and have been there for these families every step of the way when faced with good news, or not so good news.”
While there are any number of reasons people may want to learn more about how their genetics may affect their or their loved ones health, all patients want the same thing: high-quality care at the lowest cost and access to the latest technologies, diagnostics and research related to their genetic stories. In the interest of better serving these needs, the initial goals of the partnership include:
- Increasing access to clinical genetic services for MUSC patients and all South Carolinians
- Optimizing the patient journey to improve wait times for appointments and consultations
- Sharing critical resources and expertise where possible to lower costs
- Pursuing workforce development, research, clinical trials and treatment collaborations.
Nearly every child in South Carolina who was diagnosed with a genetic birth defect, developmental delay or other hereditary disorder has already been referred to GGC, due to the center’s expertise with rare conditions and commitment to new technologies and diagnostics. GGC, a nonprofit institute centered on research, clinical genetic services, diagnostic laboratory testing and educational programs and resources, is focused on compassionate patient care and innovative scientific advancement.
About Greenwood Genetic Center
The Greenwood Genetic Center (GGC), founded in 1974, is a nonprofit organization advancing the field of medical genetics and caring for families impacted by genetic disease and birth defects. At its home campus in Greenwood, South Carolina, a talented team of physicians and scientists provides clinical genetic services, diagnostic laboratory testing, educational programs and resources, and research in the field of medical genetics. GGC’s faculty and staff are committed to the goal of developing preventive and curative therapies for the individuals and families they serve. GGC extends its reach as a resource to all residents of South Carolina with satellite offices in Charleston, Columbia, Florence and Greenville. For more information about GGC please visit www.ggc.org.
Nephron partnership helps patients receive anesthetics faster see more
A new partnership between Nephron Pharmaceuticals Corp. and National Medical Products Inc. will help provide more patients with a quick and simple delivery of anesthetic medications, according to a news release from Nephron.
National Medical Products is the developer of the single-use, subcutaneous J-Tip Needle-Free Injector. Hospitals which use the injector will now be able to use Nephron-developed technology in a Luer lock syringe, buffered and pre-filled with lidocaine, to fill it.
“This new partnership is a huge win for patients, and we are extraordinarily excited to announce it,” Lou Kennedy, CEO of West Columbia-headquartered Nephron, said in the release. “Working together with the developers of J-Tip, we are making sure that the delivery of anesthetic medications is safe, easy-to-use and virtually pain-free, because patients deserve nothing less.”
California-based National Medical Products, established in 2001, refined a jet-injection technology previously used by the military for vaccine delivery to create a self-contained injector that uses compressed carbon dioxide to provide an anesthetic effect in one to two minutes, according to the release. The injector is most commonly used before procedures such as IV insertions and blood draws.
Nephron said the companies hope the partnership will help reach more patients.
Life sciences is booming across South Carolina, experts report see more
The economic future of South Carolina is being profoundly impacted by a rising industry sector that has unexpectedly achieved the distinction of becoming the fastest-growing component of the Palmetto State’s knowledge economy.
Not automotive, not aerospace, but life sciences—a huge and multifaceted trillion-dollar-plus global industry that averages almost triple the R&D of all others, comprised of multiple segments, including drugs and pharmaceuticals, medical devices and equipment, digital health solutions, research-testing-medical labs, bio-science distribution, bio-ag and other life sciences support organizations.
The pharmaceutical segment in the U.S. alone employs approximately 3.5 million people, which exceeds the population of many states. Meanwhile, the medtech and digital health segments also continue to ramp-up dramatically, fueled by innovation and disruptive global trends ranging from the transformation of healthcare delivery to the enormous impact of artificial intelligence.
According to SCBIO’s just released statewide S.C. Life Sciences Strategic Plan (Version 2.0 covering 2019-2021), an influx of new firms into the Palmetto State coupled with a comprehensive recount effort has surprisingly revealed that the number of life science companies with a presence in the Palmetto State has risen to more than 650—a figure which is over 200 more than were recognized in an initial economic impact study conducted approximately three years ago.
That foundational study funded by the state Department of Commerce and SCRA revealed an annual life sciences economic impact now conservatively approaching $12 billion, with more than 43,000 direct and indirect employees receiving wages almost double the state’s average, and an employment growth rate twice that of South Carolina as a whole. Perhaps even more compelling is the fact that life science entities are now present in 43 of 46 SC counties.
Established starring players in the Palmetto State’s rapidly evolving life sciences constellation such as Nephron Pharmaceuticals in West Columbia have grown from 400 employees to over 1,100 in the same time frame, with an accompanying capital investment close to $400 million dollars. Long-time South Carolina life science companies such as ZEUS Industrial Products in Orangeburg, Clemson University spin-out Poly-Med Inc., Sumter’s BD and Charleston’s Charles River Laboratories are achieving record employment numbers boosted by a growing global customer base.
Concurrently, new South Carolina biotech and medtech industry stars recently coming on line such as Thorne Research in Berkeley County and Arthrex in Anderson County have invested tens of millions of dollars in state-of-the-art facilities and are rapidly ramping up to projected employment levels in the hundreds.
Equally encouraging is the fact that scores of highly innovative early-stage life sciences companies like Charleston’s Firststring Research Inc.and Greenville’s Humimic Medical are becoming deeply rooted and committed to building their promising futures in South Carolina. This is a testament to the fact that a robust life sciences industry ecosystem is forming and maturing that not only supports larger scale advanced manufacturing operations, but can also foster and support innovative start-ups and early stage (pre-revenue) companies that must be uniquely bolstered in their early developmental years with a myriad of sophisticated resources, talent and funding sources in order to successfully enter the marketplace.
In years past, a multitude of promising, young South Carolina-born companies often left the state in order to obtain crucial funding and unique talent in more established bastions of life sciences such as Boston, the West Coast or even the nearby Research Triangle in North Carolina.
Gratefully, South Carolina is becoming a rising destination for both mature and early-stage life science companies that are fueled by all three of our major research universities and their extraordinary life sciences core competencies, renowned institutes such as the Greenwood Genetics Center, medical schools anchoring three major regions, the MUSC and Prisma Health science centers, and major healthcare providers.
They are also tapping into a growing bullpen of content experts in the Palmetto State ranging from experienced FDA navigators to reimbursement specialists to intellectual property attorneys and other highly specialized consultants
Based on the positive momentum of this burgeoning industry—which is virtually recession-proof and a huge diversification for South Carolina’s economy—hard-fought funding for SCBIO has reached a record high with new members joining forces with the organization on a weekly basis.
This crucial fuel is enabling unprecedented life sciences economic development strategies to be successfully mounted in the Palmetto State, including the active recruitment of a new generation of leading-edge life sciences companies into South Carolina from all over the world, in tandem and full alignment with vital state, regional and local partners—with recent economic development missions generating measurable results in Switzerland, Italy, Germany, Dubai (UAE), and across the U.S.
To achieve SCBIO’s bold vision of building the nation’s most industry-friendly and innovative life sciences ecosystem and business environment to fuel a knowledge economy in South Carolina, there is much work to be done—and it will be an endless journey. And in some respects, the Palmetto State is still somewhat fledgling as a global player in this complex and ever-changing industry. However, South Carolina’s progress over the past decade has been nothing short of remarkable, and the opportunities are endless and unlimited.
Life sciences is now uniquely igniting and demonstrably contributing to a brilliant future for the state of South Carolina. Please stay tuned—the best is yet to come.
BIO CEO Jim Greenwood tripled organization’s size, built bridges to create innovation ecosystem see more
The Biotechnology Innovation Organization (BIO) today announced that industry veteran Jim Greenwood will step down as President and CEO of the world’s largest biotechnology organization after the 2020 election and help transition a new leader to represent the industry globally and to defend innovation from domestic political attacks.
“I’ve been twice blessed – to represent the American people in Congress and then to represent the extraordinary scientists and entrepreneurs of the biotechnology industry,” Jim Greenwood said. “No organization has played a more powerful role than BIO in making sure government leaders embrace thoughtful policy so the science of biotechnology can march forward. I know because I was one of those lawmakers inspired by my BIO education. Through this organization, I came to see the miracles the biotech industry makes possible.”
“Jim’s pragmatic, ethical, patient-first leadership of BIO for more than 14 years has allowed the United States to create a pro-innovation public policy environment that’s the envy of the world, and I say that as someone who has led biopharmaceutical companies in three countries,” said BIO Chairman Jeremy Levin, CEO of Ovid Therapeutics, a biotech company working on cures for rare neurological disorders. “All of us at BIO will continue to depend on his thoughtful stewardship for the next 15 months as we fight short-sighted attempts to drain capital from our sector and curtail the intellectual property rights of innovators.”
South Carolina Life Sciences Conference to Feature BIO global CEO Jim Greenwood, Over 50 National Speakers as SCBIO 2018 Takes Center Stage October 23-25BIO global CEO Jim Greenwood, Over 50 National Speakers to Present at SCBIO 2018 see more
Conference registrations soar with sell-out expected; CEOs and top industry leaders head to Charleston for strategic partnership development, industry insights
SOUTH CAROLINA – September 26, 2018 – BIO global CEO Jim Greenwood will join more than 50 additional national speakers at SCBIO 2018 – the annual conference bringing top leaders and executives from life sciences organizations across the state and nation to Charleston, South Carolina October 23-25.
Mr. Greenwood will address the gathering with a keynote presentation entitled “Global Perspectives for Life Sciences – Compelling Opportunity for South Carolina” the morning of the conference opening on October 24. His presentation will be bracketed by two high-powered panel discussions – a feature panel comprised of top pharmaceutical executives entitled “Pharma’s Future in the Palmetto State and Beyond,” and followed by the Southeast US Economic Development Luncheon featuring an address by Secretary of Commerce Bobby Hitt. The luncheon will be capped by a panel featuring life sciences economic development CEOs from across the Southeastern region. Conference Chair and Womble Bond Dickinson partner Stephanie Yarbrough will moderate the luncheon panel.
Scores of top industry chief executives, leaders in government and higher education, biotechnology and pharma executives, clinicians and researchers, and industry supporters from across America have already registered to attend SCBIO 2018 at Charleston’s Gaillard Auditorium, with registration already doubling the pace of 2017. Among committed speakers and panelists are DePuy Synthes Global Orthopedic Leader I.V. Hall, Nephron Pharmaceuticals CEO Lou Kennedy, J.P. Morgan Executive Director of Healthcare Investment Banking Bell Zhong, MUSC President David Cole, USC President Harris Pastides, Siemens Healthineers North Americas President Dave Pacitti, and numerous others.
Themed “Connect. Collaborate. Advance!” the 2+ day conference draws attendees from across America for networking, innovation updates, opportunity discovery, partnership making and strategic discussion. Committed attendees include officials across a broad spectrum of life sciences industries including medical devices, bio manufacturing, drug discovery, pharmaceuticals, diagnostics and testing, digital health and health IT, bio ag and more. Space is limited and advance registration is still available at https://www.scbio.org/events/scbio-annual-conference.
SCBIO is South Carolina’s investor-driven economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state. The industry has an $11.4 billion economic impact in the Palmetto State, with more than 400 firms directly involved and 15,000 professionals employed in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.
SCBIO 2018 kicks off Tuesday evening October 23 with an Opening Reception for conference registrants, speakers and sponsors at The Dewberry Hotel, presented by Explore Charleston and The Dewberry. Wednesday will feature a complete day of sessions beginning at breakfast and continuing through a gala evening reception presented by Womble Bond Dickinson. The conference will wrap up Thursday at lunchtime.
“The life sciences industry is a major driver of South Carolina’s economy, and this conference is testament to the industry’s growing impact, reach and rapidly rising economic significance in our state and region,” noted SCBIO President and CEO Sam Konduros. “Already accounting for thousands of highly-skilled jobs in the Palmetto State, this sector has tremendous growth potential, and we’re excited to showcase the top companies, research universities and leaders from across our state and country at SCBIO 2018.”
Among leading biotech and med-tech industry brands participating in the conference are Nephron Pharmaceutical, BIO, Johnson & Johnson, AVX, PhRMA, DePuy Synthes, Medpoint, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, SoftBox Systems, ZEUS, Patheon Thermo Fisher and more. All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, and economic development entities including the South Carolina Department of Commerce, SCRA, the Upstate SC Alliance, the Charleston Regional Development Alliance, Central Carolina Alliance and SiMT.
As the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations – SCBIO members include hundreds of academic institutions, biotech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products that transform how we heal, fuel and feed the world.